Seres Therapeutics (MCRB) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -1145.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MCRB | NEUP |
|---|---|---|
| Share price | $1.24 | $2.35 |
| Market cap | $12.64M | $12.72M |
| 1-day change | -6.77% | +1.29% |
| YTD return | — | -39.43% |
| 1-year return | — | -47.31% |
| EPS (TTM) | $-5.01 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $789.00K | $1.17M |
| Revenue growth (YoY) | — | -92.50% |
| Net income (latest FY) | $5.70M | $-13.45M |
| Operating margin | -11910.14% | -1401.09% |
| Net margin | 721.93% | -1145.66% |
| 52-week high | $18.86 | $5.53 |
| 52-week low | $1.20 | $2.26 |
| Distance from 52-week high | -93.43% | -57.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +1270.97% | — |
| Average volume | 74.83K | 26.53K |
| Shares outstanding | 10.20M | 5.41M |
| Employees | 66 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -1145.7 cents for Neuphoria Therapeutics.
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
MCRB vs NEUP FAQ
Which is bigger, Seres Therapeutics or Neuphoria Therapeutics?
Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.64M for Seres Therapeutics (MCRB).
Are Seres Therapeutics and Neuphoria Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.